Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Regulatory News (PXS)

Share Price Information for Provexis (PXS)

Share Price is delayed by 15 minutes
Get Live Data
1.10    0.00 (0.00%)
Bid:
1.00
Ask:
1.10
Spread: 0.10 (10.00%)
Market Cap: £25.80m
PXS Live PriceLast checked at - London Stock Exchange

Intraday Provexis Share Chart

AGM Statement

24 Aug 2011 07:00

RNS Number : 9007M
Provexis PLC
24 August 2011
 



24 August 2011

Provexis plc

 

AGM Statement

 

Provexis plc ("Provexis" or the "Company"), the life-science business that develops, licenses and markets scientifically-proven functional food, sports nutrition and medical food technologies, will hold its Annual General Meeting in Reading later today.

 

At the meeting Dawson Buck, the non-executive Chairman of the Company, will give the following update on developments:

 

 "The Company has made major progress over the past 18 months, specifically with the commercialisation of its lead technology Fruitflow and the recent acquisition of Science in Sport ("SiS").

 

Following the announcement of the long-term Alliance with DSM Nutritional Products ("DSM") in June 2010, DSM has made good progress in marketing Fruitflow to a broad range of global markets, attracting positive interest from a wide range of global, multinational and national brand owners in the functional food and dietary supplement sectors. The Alliance expects to see initial revenues from Fruitflow commence in the coming months and the Company looks forward to updating shareholders on this matter as and when appropriate.

 

The Company acquired SiS in June 2011. The Board are very pleased with the business and the opportunities it presents to the enlarged group. The Board strongly believe that through targeted investment SiS will achieve significant like for like revenue growth and margin improvement. As part of this investment the Directors expect to transfer production and distribution to a larger facility later in the year, in line with growth plans for the business. Defined marketing and selling strategies, together with new product launches and efficiencies from the supply chain, will underpin sales and profit growth in the business during 2012.

 

The SiS business presents the Company with a number of opportunities to bring new products to market to support 2012 growth; consequently the Board is currently reviewing the overall project pipeline for the Company in order to allocate resource and capital in the most effective way, in line with our growth targets.

 

We have a busy year ahead of us, with the main focus of the executive team being on delivering revenues from Fruitflow and growing the sales and profitability of the SiS business. We have sufficient resources to hand to deliver our targets and I look forward to a year of strong progress."

 

-ends-

 

For further information please contact:

 

Stephen Moon, Chief Executive

Provexis plc Tel: 01753 833177

 

Bobbie Hilliam Tel: 020 7071 4317

Evolution Securities

 

Haggie Financial LLP: Tel: 020 7417 8989

Matthew Longbottom/Peter Rigby matthew.longbottom@haggie.co.uk

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMEXLFLFVFLBBB
Date   Source Headline
5th Jun 20174:35 pmRNSPrice Monitoring Extension
19th May 20174:40 pmRNSSecond Price Monitoring Extn
19th May 20174:35 pmRNSPrice Monitoring Extension
10th May 20177:01 amRNSTrading Update
10th May 20177:00 amRNSResults of Placing
2nd May 20177:15 amRNSFunding Update
11th Apr 20174:40 pmRNSSecond Price Monitoring Extn
11th Apr 20174:35 pmRNSPrice Monitoring Extension
6th Apr 20177:00 amRNSBy-Health MOU and product launch for Fruitflow
8th Feb 20174:40 pmRNSSecond Price Monitoring Extn
8th Feb 20174:35 pmRNSPrice Monitoring Extension
30th Dec 20167:00 amRNSHalf-year Report
21st Dec 20164:41 pmRNSSecond Price Monitoring Extn
21st Dec 20164:35 pmRNSPrice Monitoring Extension
20th Dec 20167:00 amRNSFruitflow and Blood Pressure - second stage update
23rd Nov 20167:00 amRNSStudy publication - comparison with aspirin
18th Nov 20169:46 amRNSNew Collaboration for Fruitflow
30th Sep 20163:33 pmRNSResult of AGM
15th Sep 20165:08 pmRNSDirector/PDMR Shareholding
7th Sep 20167:00 amRNSPreliminary Results
2nd Sep 201610:23 amRNSHolding(s) in Company
2nd Aug 20167:00 amRNSResults of Placing
12th Jul 20167:00 amRNSStudy Publication
29th Jun 20167:05 amRNSFunding Update
29th Jun 20167:00 amRNSProduct Launch
9th Jun 20162:29 pmRNSFunding Update
31st May 20167:00 amRNSTrading Update
11th Apr 20164:40 pmRNSSecond Price Monitoring Extn
11th Apr 20164:35 pmRNSPrice Monitoring Extension
25th Feb 20164:40 pmRNSSecond Price Monitoring Extn
25th Feb 20164:35 pmRNSPrice Monitoring Extension
19th Feb 20164:40 pmRNSSecond Price Monitoring Extn
19th Feb 20164:35 pmRNSPrice Monitoring Extension
7th Jan 20162:01 pmRNSDirector/PDMR Shareholding
22nd Dec 20157:00 amRNSHalf Yearly Report
30th Sep 20154:58 pmRNSResult of AGM
7th Sep 201510:47 amRNSAnnual Report and Notice of AGM
4th Sep 20157:00 amRNSPreliminary Results
21st Jul 20153:41 pmRNSHolding(s) in Company
3rd Jul 20157:00 amRNSPlacing of shares via Primarybid.com
29th Jun 20157:00 amRNSUpdate of Collaboration with University of Oslo
4th Jun 20157:00 amRNSEnhanced terms for Fruitflow Alliance Agreement
24th Apr 20154:35 pmRNSPrice Monitoring Extension
20th Feb 20152:34 pmRNSFruitflow - New Product Video
19th Jan 20154:40 pmRNSSecond Price Monitoring Extn
19th Jan 20154:35 pmRNSPrice Monitoring Extension
30th Dec 20147:00 amRNSHalf Yearly Report
9th Dec 20147:00 amRNSDraw Down of Funds and Issue of Equity
1st Dec 20147:00 amRNSRe-appointment to the Scientific Advisory Board
18th Nov 20147:00 amRNSCollaboration with the University of Oslo

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.